BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.72
-0.24 (-2.68%)
At close: Jul 15, 2025, 4:00 PM
8.73
+0.01 (0.11%)
After-hours: Jul 15, 2025, 5:09 PM EDT
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $145.53M in the quarter ending March 31, 2025, with 56.89% growth. This brings the company's revenue in the last twelve months to $503.49M, up 41.67% year-over-year. In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth.
Revenue (ttm)
$503.49M
Revenue Growth
+41.67%
P/S Ratio
3.69
Revenue / Employee
$868,078
Employees
580
Market Cap
1.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
| Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
| Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
| Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
| Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BCRX News
- 6 days ago - BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewsWire
- 8 days ago - BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewsWire
- 12 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million - GlobeNewsWire
- 4 weeks ago - BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI - GlobeNewsWire
- 4 weeks ago - ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewsWire
- 5 weeks ago - BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewsWire
- 6 weeks ago - BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewsWire